aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for pediatric and other cancers, including solid tumors. The company's mission is to provide innovative treatments that address unmet medical needs in oncology. Salarius is dedicated to advancing its lead candidate, Seclidemstat, which targets various forms of cancer. The firm primarily serves patients in the United States, aiming to improve outcomes and quality of life for those affected by these serious conditions.
Salarius Pharmaceuticals has achieved significant milestones, including presenting clinical data on Seclidemstat at the European Hematology Association Annual Meeting and receiving clearance to begin a Phase I trial for SP-2577 in non-Hodgkin lymphoma. These advancements underscore the company's commitment to pioneering cancer therapies. Salarius continues to participate in key industry events, such as the Annual Tumor Models Conference, further establishing its presence in the oncology research community.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
United States
When was Salarius Pharmaceuticals founded?
Salarius Pharmaceuticals was founded in 2010.
Where is Salarius Pharmaceuticals’s headquarters located?
Salarius Pharmaceuticals’s headquarters is located in Houston, US.
When was Salarius Pharmaceuticals’s last funding round?
Salarius Pharmaceuticals’s most recent funding round was for $6M (USD) in May 2023.
How many employees does Salarius Pharmaceuticals have?
Salarius Pharmaceuticals has 12 employees as of Feb 6, 2024.
How much has Salarius Pharmaceuticals raised to-date?
As of July 05, 2023, Salarius Pharmaceuticals has raised a total of $51.2M (USD) since May 12, 2023.
Add Comparison
Total Raised to Date
$51.2M
USD
Last Update May 12, 2023
Last Deal Details
$6M
USD
May 12, 2023
Post Ipo Equity
Total Employees Over Time
12
As of Feb 2024
Salarius Pharmaceuticals Address
2450 Holcombe Blvd
suite j-608
Houston,
77021
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts